Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1998 1
1999 1
2000 3
2001 4
2002 1
2003 6
2004 2
2005 3
2006 6
2007 5
2008 10
2009 4
2010 15
2011 10
2012 21
2013 15
2014 14
2015 18
2016 12
2017 11
2018 14
2019 11
2020 17
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

188 results
Results by year
Filters applied: . Clear all
Page 1
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Seppi K, et al. Among authors: fox sh. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Mov Disord. 2019. PMID: 30653247 Free PMC article. Review.
OBJECTIVE: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD). BACKGROUND: The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations fo …
OBJECTIVE: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD) …
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee. Fox SH, et al. Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570866 Review.
OBJECTIVE: The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). BACKGROUND: The Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments o …
OBJECTIVE: The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how.
de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. de Bie RMA, et al. Among authors: fox sh. Lancet Neurol. 2020 May;19(5):452-461. doi: 10.1016/S1474-4422(20)30036-3. Epub 2020 Mar 12. Lancet Neurol. 2020. PMID: 32171387 Review.
Debate is ongoing regarding when, why, and how to initiate pharmacotherapy for Parkinson's disease. Early initiation of dopaminergic therapies does not convey disease-modifying effects but does reduce disability. ...Until more effective methods of prov …
Debate is ongoing regarding when, why, and how to initiate pharmacotherapy for Parkinson's disease. Early initiation of …
Update in therapeutic strategies for Parkinson's disease.
Kulisevsky J, Oliveira L, Fox SH. Kulisevsky J, et al. Among authors: fox sh. Curr Opin Neurol. 2018 Aug;31(4):439-447. doi: 10.1097/WCO.0000000000000579. Curr Opin Neurol. 2018. PMID: 29746402 Review.
Specific therapeutics for cognition, swallowing, sleep, and mood disorders had moderate to limited benefits. Exercise-based therapy appears beneficial at all stages of Parkinson's disease. SUMMARY: The motor symptoms of Parkinson's dis
Specific therapeutics for cognition, swallowing, sleep, and mood disorders had moderate to limited benefits. Exercise-based therapy a …
Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.
Chang A, Fox SH. Chang A, et al. Among authors: fox sh. Drugs. 2016 Jul;76(11):1093-118. doi: 10.1007/s40265-016-0600-5. Drugs. 2016. PMID: 27312429 Review.
Psychotic symptoms are common in Parkinson's disease (PD) and are associated with poorer quality of life and increased caregiver burden. PD psychosis is correlated with several factors, such as more advanced disease, cognitive impairment, depression, a …
Psychotic symptoms are common in Parkinson's disease (PD) and are associated with poorer quality of life and increased …
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.
Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE. Espay AJ, et al. Among authors: fox sh. Ann Neurol. 2018 Dec;84(6):797-811. doi: 10.1002/ana.25364. Epub 2018 Nov 30. Ann Neurol. 2018. PMID: 30357892 Review.
Levodopa-induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa-to-dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergi …
Levodopa-induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of …
Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease.
Lizarraga KJ, Fox SH, Strafella AP, Lang AE. Lizarraga KJ, et al. Among authors: fox sh. Clin Geriatr Med. 2020 Feb;36(1):105-118. doi: 10.1016/j.cger.2019.09.004. Epub 2019 Sep 6. Clin Geriatr Med. 2020. PMID: 31733691 Review.
Psychotic and compulsive symptoms in Parkinson disease are highly prevalent and associated with poor outcomes and greater caregiver burden. ...When chronic, comorbid systemic illnesses, dementia, and psychiatric disorders should be considered. Reduction and d …
Psychotic and compulsive symptoms in Parkinson disease are highly prevalent and associated with poor outcomes and greater care …
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. Gonzalez-Latapi P, et al. Among authors: fox sh. CNS Drugs. 2020 Oct;34(10):1025-1044. doi: 10.1007/s40263-020-00754-0. CNS Drugs. 2020. PMID: 32785890 Review.
Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy. ...
Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) moto …
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. Seppi K, et al. Among authors: fox sh. Mov Disord. 2011 Oct;26 Suppl 3(0 3):S42-80. doi: 10.1002/mds.23884. Mov Disord. 2011. PMID: 22021174 Free PMC article. Review.
The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor sympt …
The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Diseas
Novel Levodopa Formulations for Parkinson's Disease.
Freitas ME, Ruiz-Lopez M, Fox SH. Freitas ME, et al. Among authors: fox sh. CNS Drugs. 2016 Nov;30(11):1079-1095. doi: 10.1007/s40263-016-0386-8. CNS Drugs. 2016. PMID: 27743318 Review.
Levodopa remains the most effective treatment for Parkinson's disease and is considered the gold standard therapy. However, disease progression and changes in the gastrointestinal tract result in a declining window of treatment response in a majority o …
Levodopa remains the most effective treatment for Parkinson's disease and is considered the gold standard therapy. Howe …
188 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page